Briganti Lab
Welcome to the Briganti Lab
Cardiovascular disease is the leading cause of death in the United States. However, in 2023 the FDA approved 14 new drugs for cancer and only one new drug for cardiovascular disease. While many of the new cancer therapies are personalized, the one drug approved for cardiovascular disease has a poorly understood mechanism of action. The Briganti lab uses a combination of stem cell and genome editing technology, functional genomics, and phenotypic models to uncover distinct mechanisms in heart disease associated with distinct mutations. Our aim is to develop precise, mechanism-based therapeutics to fulfil the vision of “treating the right patient with the right drug at the right time.”
We're Hiring!
We are recruiting Postdoctoral fellows, technicians, and graduate and undergraduate students.
For additional info and to apply visit our Career page.